Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.
Acute myeloid leukemia (AML) has posed significant therapeutic challenges to pediatric oncologists. Despite intensive therapy, half of the children with AML relapse and die from their disease. Efforts to identify risk factors in AML are directed toward defining populations who may benefit from alternative therapies. Patients at lower risk for relapse may benefit from treatment de-escalation, sparing them adverse side effects. Management of high-risk patients may prove more difficult, as the nearly myeloablative nature of AML therapy leaves little room for therapy escalation short of stem cell transplantation. This review evaluates prognostic factors in pediatric AML and discusses the feasibility of using these factors in risk-adapted therapy regimens.
Meshinchi
Soheil
S
Fred Hutchinson Cancer Research Center, University of Washington, Department of Pediatrics, Division of Clinical Research, Seattle, Washington, USA.
Arceci
Robert J
RJ
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D033581:Stem Cell Transplantation
D000970:Antineoplastic Agents